“We have the capacity to produce over 10M COVID-19 tests per week globally”
Bio Spectrum|October 2020
Thermo Fisher Scientific, the world leader in serving science, is continuously working to expand global capacity and capabilities across its leading pharma services network to support customers in government, industry and academia as they accelerate development and production of COVID-19 vaccines, therapies and other treatments.
Dr Manbeena Chawla
“We have the capacity to produce over 10M COVID-19 tests per week globally”

The company is now supporting over 200 projects globally. The company is also supporting multiple vaccine programmes globally that are in or entering human clinical trials, providing critical capacity and expertise that has accelerated development and readiness by months. In addition to its work on COVID-19-related vaccines and therapies, the company continues to ensure that patients undergoing clinical trials continue to receive the critical medicines they need during this crisis. Amit Chopra, Managing Director, India and Middle East, Thermo Fisher Scientific, Mumbai recently spoke to BioSpectrum about the company’s initiatives to counter COVID-19, particularly in India. Edited excerpts;

How is Thermo Fisher Scientific expanding its diagnostic capacity to fight the global pandemic?

At Thermo Fisher Scientific, our mission is to enable our customers to make the world healthier, cleaner, and safer. Globally, we saw a significant increase in the spread of the virus and our customers were getting inundated. As reliable partners, our primary objective was to scale our offerings to enable them to better navigate through this pandemic. We have been actively involved in understanding the structure of the virus, developing new diagnostic tests, providing personal protective equipment, reagents, and other laboratory essential instruments, to providing tools for vaccine research and development, clinical trials and even manufacturing some of the therapeutics. TaqPath COVID-19 Combo Kits were one of the first tests to receive Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) and are being extensively used across the world.

Esta historia es de la edición October 2020 de Bio Spectrum.

Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.

Esta historia es de la edición October 2020 de Bio Spectrum.

Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.

MÁS HISTORIAS DE BIO SPECTRUMVer todo
Sartorius Stedim Biotech opens new centre for bioprocess innovation in US
Bio Spectrum

Sartorius Stedim Biotech opens new centre for bioprocess innovation in US

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, has opened its new centre for Bioprocess Innovation in Marlborough, Massachusetts in the US.

time-read
1 min  |
BioSpectrum India Jan 2025
Agilent introduces innovative Mito-rOCR assay kit for mitochondrial research
Bio Spectrum

Agilent introduces innovative Mito-rOCR assay kit for mitochondrial research

Agilent Technologies Inc. has announced the new MitorOCR Assay Kit.

time-read
1 min  |
BioSpectrum India Jan 2025
Qiagen launches AI-extension of Ingenuity Pathway Analysis for automatic interpretation of biological data
Bio Spectrum

Qiagen launches AI-extension of Ingenuity Pathway Analysis for automatic interpretation of biological data

Qiagen has announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new feature designed to simplify and accelerate the interpretation of complex biological data.

time-read
1 min  |
BioSpectrum India Jan 2025
Parse Biosciences announces expansion of Evercode BCR product line
Bio Spectrum

Parse Biosciences announces expansion of Evercode BCR product line

Parse Biosciences, a leader in scalable single cell sequencing solutions, has announced the expansion of its Evercode BCR product line to enable applications in mice.

time-read
1 min  |
BioSpectrum India Jan 2025
New technology for unambiguous detection of HIV genome using tailored fluorogenic tests
Bio Spectrum

New technology for unambiguous detection of HIV genome using tailored fluorogenic tests

A team of scientists at Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), has developed a novel diagnostic technology known as the GQ Topology-Targeted Reliable Conformational Polymorphism (GQ-RCP) platform.

time-read
1 min  |
BioSpectrum India Jan 2025
Gene mutation likely cause for developing autism in early childhood: RGCB study
Bio Spectrum

Gene mutation likely cause for developing autism in early childhood: RGCB study

Autism, a developmental disorder that causes functional abnormalities in brain development, is caused by a combination of environmental and genetic factors with its symptoms manifesting in childhood as early as the age of two years.

time-read
1 min  |
BioSpectrum India Jan 2025
IIIT-Delhi unveils AI platform for discovering molecules that promote healthy ageing
Bio Spectrum

IIIT-Delhi unveils AI platform for discovering molecules that promote healthy ageing

A team of researchers from Indraprastha Institute of Information Technology Delhi (IIIT-Delhi) has developed AgeXtend, a groundbreaking artificial intelligence (AI)-based platform that is set to transform the search for molecules promoting healthy ageing.

time-read
1 min  |
BioSpectrum India Jan 2025
RSSDI study lays focus on Yoga and Diabetes Prevention
Bio Spectrum

RSSDI study lays focus on Yoga and Diabetes Prevention

Dr Jitendra Singh, Union Minister of State (Independent Charge) for Science and Technology, recently released the landmark study by Research Society for Study of Diabetes in India (RSSDI) on 'Yoga and Diabetes Prevention'.

time-read
1 min  |
BioSpectrum India Jan 2025
Dr Alok Khullar steps in as Group CEO of RJ Corp Healthcare
Bio Spectrum

Dr Alok Khullar steps in as Group CEO of RJ Corp Healthcare

RJ Corp Healthcare, a leading name in the healthcare sector through its renowned entities Cocoon Hospital and Cryoviva Stem Cell Bank, has announced the appointment of Dr Alok Khullar as Group Chief Executive Officer (CEO).

time-read
1 min  |
BioSpectrum India Jan 2025
Entod Pharmaceuticals on-boards Dr Anish Desai as Scientific & Research adviser
Bio Spectrum

Entod Pharmaceuticals on-boards Dr Anish Desai as Scientific & Research adviser

Mumbai-based Entod Pharmaceuticals has appointed Dr Anish Desai as its Scientific and Research Adviser.

time-read
1 min  |
BioSpectrum India Jan 2025